Related Experiment Videos
Absence of p18 mutations or deletions in lymphoid malignancies
T Otsuki1, E S Jaffe, A Wellmann
1Hematopathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Abstract:
p18 is a recently described cyclin-dependent kinase inhibitor (CDK-I) wih homology to p16 and p15. The latter two CDK-Is have been implicated as possible tumor suppressor genes in a wide variety of human tumors, including hematological malignancies. Because of p18's structural and functional homology to p16 and p15, we hypothesized that it may also function as a tumor suppressor gene in some lymphoid malignancies. To explore this possibility we examined 81 primary lymphoid tumors for deletion and mutation p18. The primary tumors included 40 T cell malignancies and 41 B cell malignancies. None of the lymphoid tumors studied possessed deletions of p18, including a group of lymphoblastic lymphomas which we previously reported to have deletions of p16 and p15. PCR-SSCP analysis of the p18 gene identified a single polymorphism of codon 114, but failed to demonstrate mutations in any of the lymphoid tumors. These results do not support a role for p18 in the pathogenesis of the lymphoid neoplasms studied.
Insights
The study investigated the p18 gene in lymphoid tumors. Researchers found no deletions or mutations, suggesting p18 does not act as a tumor suppressor in these cancers.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- p18 is a cyclin-dependent kinase inhibitor (CDK-I) structurally similar to p16 and p15.
- p16 and p15 are implicated as tumor suppressor genes in various human cancers, including hematological malignancies.
Purpose of the Study:
- To investigate the potential role of the p18 gene as a tumor suppressor in lymphoid malignancies.
- To examine primary lymphoid tumors for deletions and mutations in the p18 gene.
Main Methods:
- Analysis of 81 primary lymphoid tumors (40 T cell, 41 B cell) for p18 gene deletions.
- PCR-SSCP analysis to detect mutations in the p18 gene across the studied tumors.
Main Results:
- No deletions of the p18 gene were found in any of the 81 lymphoid tumors analyzed.
- A single polymorphism at codon 114 was identified, but no mutations were detected in the p18 gene.
- These findings do not support a role for p18 in the pathogenesis of the studied lymphoid neoplasms.
Conclusions:
- The study concludes that p18 does not appear to function as a tumor suppressor gene in the investigated lymphoid malignancies.
- The absence of p18 deletions or mutations suggests it is not a key player in the development of these specific cancers.